Literature DB >> 2285303

Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

A B Clarkson1, M Sarić, R W Grady.   

Abstract

The iron chelator deferoxamine and the polyamine biosynthesis inhibitor eflornithine (DL-alpha-difluoromethylornithine) were examined for anti-Pneumocystis carinii activity in the rat model of P. carinii pneumonia. The activity of deferoxamine at 250, 500, and 1,000 mg/kg given intraperitoneally provides evidence that iron chelation is a promising novel approach to P. carinii chemotherapy. Results with eflornithine at 2, 3, and 4% in drinking water confirm and extend previously reported activity in the rat model.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2285303      PMCID： PMC171942          DOI： 10.1128/AAC.34.9.1833

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Pulmonary involvement in the acquired immunodeficiency syndrome.

Authors:  P C Hopewell; J M Luce
Journal:  Chest       Date:  1985-01       Impact factor: 9.410

2.  Antimalarial effect of HBED and other phenolic and catecholic iron chelators.

Authors:  A M Yinnon; E N Theanacho; R W Grady; D T Spira; C Hershko
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

3.  Treatment of Pneumocystis carinii pneumonitis. A comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the Children's Cancer Study Group.

Authors:  S E Siegel; L J Wolff; R L Baehner; D Hammond
Journal:  Am J Dis Child       Date:  1984-11

4.  A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron.

Authors:  T E Peto; J L Thompson
Journal:  Br J Haematol       Date:  1986-06       Impact factor: 6.998

5.  Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys.

Authors:  S Pollack; R N Rossan; D E Davidson; A Escajadillo
Journal:  Proc Soc Exp Biol Med       Date:  1987-02

6.  Assessment of therapy for pneumocystis carinii pneumonia. PCP Therapy Project Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

7.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome.

Authors:  L A Engelberg; C W Lerner; M L Tapper
Journal:  Am Rev Respir Dis       Date:  1984-10

9.  Plasmodium vinckei: suppression of mouse infections with desferrioxamine B.

Authors:  G Fritsch; J Treumer; D T Spira; A Jung
Journal:  Exp Parasitol       Date:  1985-10       Impact factor: 2.011

10.  Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine.

Authors:  C Raventos-Suarez; S Pollack; R L Nagel
Journal:  Am J Trop Med Hyg       Date:  1982-09       Impact factor: 2.345
View more
  16 in total

1.  Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii.

Authors:  S Merali; M Saric; K Chin; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Iron metabolism in the lower respiratory tract.

Authors:  F Mateos; J H Brock; J L Pérez-Arellano
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

3.  Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.

Authors:  S Merali; K Chin; R W Grady; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

Authors:  K Chin; S Merali; M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Continuous axenic cultivation of Pneumocystis carinii.

Authors:  S Merali; U Frevert; J H Williams; K Chin; R Bryan; A B Clarkson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.

Authors:  M T Cushion; F Chen; N Kloepfer
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.

Authors:  P D Walzer; J Foy; J Runck; P Steele; M White; R S Klein; B A Otter; R J Sundberg
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.

Authors:  M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.